In Vivo Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1.

IF 4.6 3区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Human gene therapy Pub Date : 2026-10-01 Epub Date: 2026-06-16 DOI:10.1177/10430342261460681
Jenny A Greig, Camilo Breton, Melanie K Smith, Thomas Furmanak, Peter Bell, Peter Clark, James M Wilson
{"title":"<i>In Vivo</i> Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1.","authors":"Jenny A Greig, Camilo Breton, Melanie K Smith, Thomas Furmanak, Peter Bell, Peter Clark, James M Wilson","doi":"10.1177/10430342261460681","DOIUrl":null,"url":null,"abstract":"<p><p>Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disorder that leads to kidney and liver failure. PH1 is caused by a mutation in the alanine glyoxylate aminotransferase (<i>AGXT</i>) gene, which encodes a key metabolic enzyme that converts glyoxylate to glycine in the liver. Inability to metabolize glyoxylate leads to oxalate overproduction, yielding insoluble calcium oxalate crystals; accumulation of these crystals leads to progressive organ failure. Here, we used a novel, minimally disruptive genome-editing approach to disrupt the mechanism of action of hydroxyacid oxidase 1 (HAO1), an upstream enzyme in the glyoxylate metabolic pathway. Successful gene editing and disruption of the <i>HAO1</i> gene is expected to increase levels of glycolate, a harmless intermediate of the glycine metabolic pathway, thereby preventing the formation of calcium oxalate crystals. We intravenously administered an adeno-associated virus (AAV) vector expressing the M1HAO1 meganuclease to both wild-type and <i>Agxt<sup>-/-</sup></i> mice, a mouse model of PH1. We observed >30% editing of <i>HAO1</i> in <i>Agxt<sup>-/-</sup></i> mice, correlating with a dose-dependent increase in serum glycolate levels. At the highest dose tested, urine glycolate levels increased by 79%, with a concomitant 75% decrease in urine oxalate levels. We also evaluated <i>in vivo</i> targeting in rhesus macaques injected with AAV expressing two different versions of the HAO1 meganuclease. Dose-dependent editing of hepatic DNA and RNA was achieved, and serum glycolate levels changed in a manner consistent with successful liver editing; additionally, the treatment was well tolerated. Our results indicate that AAV-delivered meganucleases can effectively target <i>HAO1</i> in mice and nonhuman primates to achieve high levels of <i>HAO1</i> gene editing. Moreover, increased glycolate levels in serum indicate that this intervention significantly impacts the HAO1-mediated glycolate-to-glyoxylate pathway. These data suggest that this approach may represent an effective treatment for PH1.</p>","PeriodicalId":13007,"journal":{"name":"Human gene therapy","volume":" ","pages":"963-974"},"PeriodicalIF":4.6000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10430342261460681","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disorder that leads to kidney and liver failure. PH1 is caused by a mutation in the alanine glyoxylate aminotransferase (AGXT) gene, which encodes a key metabolic enzyme that converts glyoxylate to glycine in the liver. Inability to metabolize glyoxylate leads to oxalate overproduction, yielding insoluble calcium oxalate crystals; accumulation of these crystals leads to progressive organ failure. Here, we used a novel, minimally disruptive genome-editing approach to disrupt the mechanism of action of hydroxyacid oxidase 1 (HAO1), an upstream enzyme in the glyoxylate metabolic pathway. Successful gene editing and disruption of the HAO1 gene is expected to increase levels of glycolate, a harmless intermediate of the glycine metabolic pathway, thereby preventing the formation of calcium oxalate crystals. We intravenously administered an adeno-associated virus (AAV) vector expressing the M1HAO1 meganuclease to both wild-type and Agxt-/- mice, a mouse model of PH1. We observed >30% editing of HAO1 in Agxt-/- mice, correlating with a dose-dependent increase in serum glycolate levels. At the highest dose tested, urine glycolate levels increased by 79%, with a concomitant 75% decrease in urine oxalate levels. We also evaluated in vivo targeting in rhesus macaques injected with AAV expressing two different versions of the HAO1 meganuclease. Dose-dependent editing of hepatic DNA and RNA was achieved, and serum glycolate levels changed in a manner consistent with successful liver editing; additionally, the treatment was well tolerated. Our results indicate that AAV-delivered meganucleases can effectively target HAO1 in mice and nonhuman primates to achieve high levels of HAO1 gene editing. Moreover, increased glycolate levels in serum indicate that this intervention significantly impacts the HAO1-mediated glycolate-to-glyoxylate pathway. These data suggest that this approach may represent an effective treatment for PH1.

体内基因组编辑方法破坏羟基酸氧化酶1治疗原发性高草酸尿1型
原发性高草酸尿1型(PH1)是一种罕见的常染色体隐性遗传病,可导致肾脏和肝脏衰竭。PH1是由丙氨酸乙醛酸氨基转移酶(AGXT)基因突变引起的,该基因编码一种在肝脏中将乙醛酸盐转化为甘氨酸的关键代谢酶。不能代谢乙醛酸盐导致草酸过量产生,产生不溶性草酸钙晶体;这些晶体的积累会导致进行性器官衰竭。在这里,我们使用了一种新颖的、破坏性最小的基因组编辑方法来破坏羟基酸氧化酶1 (HAO1)的作用机制,这是乙氧酸代谢途径中的上游酶。成功的基因编辑和对HAO1基因的破坏有望增加甘氨酸代谢途径中无害的中间体乙醇酸的水平,从而阻止草酸钙晶体的形成。我们将表达M1HAO1巨核酶的腺相关病毒(AAV)载体静脉注射到野生型和PH1小鼠模型Agxt-/-小鼠身上。我们在Agxt-/-小鼠中观察到> - 30%的HAO1编辑,与血清乙醇酸水平的剂量依赖性增加相关。在测试的最高剂量下,尿中乙醇酸水平增加了79%,同时尿中草酸水平降低了75%。我们还在恒河猴体内评估了注射表达两种不同版本HAO1巨核酶的AAV的靶向性。实现了肝脏DNA和RNA的剂量依赖性编辑,血清乙醇酸水平以与成功的肝脏编辑一致的方式改变;此外,治疗耐受性良好。我们的研究结果表明,aav递送的巨核酶可以有效地靶向小鼠和非人灵长类动物的HAO1,从而实现高水平的HAO1基因编辑。此外,血清中乙醇酸水平的升高表明这种干预显著影响了hao1介导的乙醇酸-乙醛酸途径。这些数据表明,这种方法可能是治疗PH1的有效方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Human gene therapy
Human gene therapy 医学-生物工程与应用微生物
CiteScore
6.50
自引率
4.80%
发文量
131
审稿时长
4-8 weeks
期刊介绍: Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书